ZyVersa Therapeutics, Inc. (ZVSA) Form 8-K — Jul 10, 2026

Independent director Min Chul Park resigned from the ZyVersa Therapeutics Board and its Compensation and Nominating Committees effective July 8, 2026, citing personal reasons rather than any disagreement with the company. To address limited cash resources, the Board and management are implementing cost-cutting measures, including voluntary reductions in compensation for Chief Executive Officer Stephen Glover and Chief Financial Officer Peter Wolfe.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.